NCT02398500View on ClinicalTrials.gov

Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

July 22, 2015

Primary Completion Date

February 29, 2016

Study Completion Date

May 20, 2016

Conditions
Age-related Macular Degeneration (AMD)
Interventions
BIOLOGICAL

LMG324

IVT injection

BIOLOGICAL

Ranibizumab 0.5 mg

IVT injection

BIOLOGICAL

Sham

Fake injection used for masking purposes

Trial Locations (1)

76134

Call Alcon Call Center for Trial Locations, Fort Worth

Sponsors

Lead Sponsor

Alcon Research
All Listed Sponsors
collaborator

Novartis Institutes for BioMedical Research

OTHER

lead

Alcon Research

INDUSTRY